This site is intended for healthcare professionals
News

Phase III LINC-4 study of Isturisa for the treatment of patients with Cushing’s disease.- Recordati

Read time: 1 mins
Last updated:16th Mar 2021
Published:18th Jun 2020
Recordati announces positive results from the large Phase III LINC-4 study of Isturisa (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Condition: Cushing's Syndrome
Type: drug
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest